
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
“I just hope that people are as enthusiastic about this new company, as [I] and my coauthors are,” says Ruchika Talwar, MD.
In this video, Ruchika Talwar, MD, shares the take-home message from the recent Journal of Urology paper, “Urologic Drug Price Stewardship – Potential Cost Savings Based on the Mark Cuban Cost Plus Drug Company Model.” Talwar is a urologic oncology fellow at Vanderbilt University Medical Center in Nashville, Tennessee.






